Athenex (ATNXQ) 10-Q 6 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	ATNX
Entity Registrant Name	ATHENEX, INC.
Entity Central Index Key	0001300699
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		93,512,700
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38112
Entity Tax Identification Number	43-1985966
Entity Address, Address Line One	1001 Main Street
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Buffalo
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14203
City Area Code	716
Local Phone Number	427-2950
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 47,980	$ 69,587
Restricted cash	16,500	16,500
Short-term investments	123,186	138,636
Accounts receivable, net of chargebacks and other deductions of $17,264 and $12,552, respectively, and provision for credit losses of $9,482 and $9,637, respectively	20,189	23,603
Inventories	26,324	28,846
Prepaid expenses and other current assets	16,968	14,789
Total current assets	251,147	291,961
Property and equipment, net	41,778	34,388
Goodwill	38,840	38,891
Intangible assets, net	9,482	10,218
Operating lease right-of-use assets, net	7,462	7,921
Other assets	947	950
Total assets	349,656	384,329
Current liabilities:
Accounts payable	15,858	18,673
Accrued expenses	28,714	38,273
Current portion of operating lease liabilities	3,161	3,185
Current portion of long-term debt and finance lease obligations	1,970	2,010
Total current liabilities	49,703	62,141
Long-term liabilities:
Long-term operating lease liabilities	5,832	6,355
Long-term debt and finance lease obligations	147,265	146,577
Deferred tax liabilities	58	56
Other long-term liabilities	3,674	3,852
Total liabilities	206,532	218,981
Commitments and contingencies (See Note 15)
Stockholders' equity:
Common stock, par value $0.001 per share, 250,000,000 shares authorized at March 31, 2021 and December 31, 2020; 95,185,620 and 95,066,195 shares issued at March 31, 2021 and December 31, 2020, respectively; 93,512,700 and 93,393,275 shares outstanding at March 31, 2021 and December 31, 2020, respectively	95	95
Additional paid-in capital	904,950	901,864
Accumulated other comprehensive loss	(841)	(1,134)
Accumulated deficit	(738,694)	(713,644)
Less: treasury stock, at cost; 1,672,920 shares at March 31, 2021 and December 31, 2020	(7,406)	(7,406)
Total Athenex, Inc. stockholders' equity	158,104	179,775
Non-controlling interests	(14,980)	(14,427)
Total stockholders' equity	143,124	165,348
Total liabilities and stockholders' equity	$ 349,656	$ 384,329

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Accounts receivable, chargebacks and other deductions (in dollars)	$ 17,264	$ 12,552
Provision for credit losses (in dollars)	$ 9,482	$ 9,637
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	95,185,620	95,066,195
Common Stock, shares outstanding	93,512,700	93,393,275
Treasury stock, shares	1,672,920	1,672,920

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Total revenue	$ 41,025	$ 46,935
Cost of sales	16,405	19,572
Gross Profit	24,620	27,363
Operating expenses:
Research and development expenses	23,070	17,192
Selling, general, and administrative expenses	22,120	25,748
Total operating expenses	45,190	42,940
Operating loss	(20,570)	(15,577)
Interest income	29	413
Interest expense	4,908	1,673
Loss before income tax expense	(25,449)	(16,837)
Income tax expense	154	2,881
Net loss	(25,603)	(19,718)
Less: net loss attributable to non-controlling interests	(553)	(289)
Net loss attributable to Athenex, Inc.	(25,050)	(19,429)
Unrealized gain (loss) on investment, net of income taxes	16	(68)
Foreign currency translation adjustment, net of income taxes	277	(438)
Comprehensive loss	$ (24,757)	$ (19,935)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (See Note 12)	$ (0.27)	$ (0.24)
Weighted-average shares used in computing net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (See Note 12)	93,429,935	81,539,548
Product Sales, Net
Revenue:
Total revenue	$ 20,360	$ 18,547
License and Other Revenue
Revenue:
Total revenue	$ 20,665	$ 28,388

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Total Athenex, Inc. Stockholders' Equity	Non-Controlling Interests
Beginning balance at Dec. 31, 2019	$ 175,855	$ 83	$ 763,648	$ (567,465)	$ (635)	$ (7,406)	$ 188,225	$ (12,370)
Beginning balance, shares at Dec. 31, 2019		83,231,063				(1,672,920)
Stock-based compensation cost	1,864		1,864				1,864
Restricted stock expense	397		397				397
Restricted stock expense, shares		(3,000)
Stock options exercised	344		344				344
Stock options exercised, shares		70,200
Net loss	(19,718)			(19,429)			(19,429)	(289)
Other comprehensive income (loss), net of tax	(506)				(506)		(506)
Ending balance at Mar. 31, 2020	158,236	$ 83	766,253	(586,894)	(1,141)	$ (7,406)	170,895	(12,659)
Ending balance, shares at Mar. 31, 2020		83,298,263				(1,672,920)
Beginning balance at Dec. 31, 2020	165,348	$ 95	901,864	(713,644)	(1,134)	$ (7,406)	179,775	(14,427)
Beginning balance, shares at Dec. 31, 2020		95,066,195				(1,672,920)
Stock-based compensation cost	2,205		2,205				2,205
Restricted stock expense	29		29				29
Stock options exercised	$ 852		852				852
Stock options exercised, shares	119,425	119,425
Net loss	$ (25,603)			(25,050)			(25,050)	(553)
Other comprehensive income (loss), net of tax	293				293		293
Ending balance at Mar. 31, 2021	$ 143,124	$ 95	$ 904,950	$ (738,694)	$ (841)	$ (7,406)	$ 158,104	$ (14,980)
Ending balance, shares at Mar. 31, 2021		95,185,620				(1,672,920)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (25,603)	$ (19,718)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,274	1,086
Stock-based compensation expense	2,234	2,261
Amortization of debt discount	779	256
Loss on disposal of assets and impairment charges		173
Deferred income taxes	2	48
Changes in operating assets and liabilities:
Receivables, net	3,414	(34,728)
Prepaid expenses and other assets	(2,176)	3,748
Inventories	2,523	(3,101)
Accounts payable and accrued expenses	(12,323)	4,430
Net cash used in operating activities	(29,876)	(45,545)
Cash flows from investing activities:
Purchase of property and equipment	(7,341)	(1,736)
Payments for licenses	(1,088)	(64)
Purchases of short-term investments	(55,784)	(23,571)
Sales and maturities of short-term investments	71,250	14,920
Net cash provided by (used in) investing activities	7,037	(10,451)
Cash flows from financing activities:
Proceeds from issuance of debt		435
Proceeds from exercise of stock options	852	344
Repayment of finance lease obligations and long-term debt	(98)	(47)
Net cash provided by financing activities	754	732
Net decrease in cash, cash equivalents, and restricted cash	(22,085)	(55,264)
Cash, cash equivalents, and restricted cash, beginning of period	86,087	127,674
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	478	(427)
Cash, cash equivalents, and restricted cash, end of period (See Note 3)	64,480	71,983
Supplemental cash flow disclosures
Interest paid	7,708	1,390
Non-cash investing and financing activities:
Accrued purchases of property and equipment	1,215	1,009
Accrued purchases of licenses	$ 1,800	500
ROU assets derecognized from modification of operating lease obligations		(468)
ROU assets recognized in exchange for operating lease obligations		$ 353

Company and Nature of Business

Company and Nature of Business	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Company and Nature of Business	1. Company and Nature of Business Organization and Description of Business Athenex, Inc. and subsidiaries (the “Company” or “Athenex”), originally under the name Kinex Pharmaceuticals LLC (“Kinex”), formed in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015. Athenex is a biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The Company has assembled a strong and experienced leadership team and has established operations across the pharmaceutical value chain to execute our goal of becoming a leader in bringing innovative cancer treatments to the market and improving health outcomes. The Company is organized around three operating segments: (1) its Oncology Innovation Platform, dedicated to the research and development of our proprietary drugs; (2) its Commercial Platform, focused on the sales and marketing of our specialty drugs and the market development of our proprietary drugs; and (3) its Global Supply Chain Platform, dedicated to providing a stable and efficient supply of APIs for our clinical and commercial efforts. The Company’s current clinical pipeline in the Oncology Innovation Platform is derived from four different proprietary technologies: (1) Orascovery, based on a P-glycoprotein (“P-gp”) pump inhibitor, (2) Src Kinase Inhibition, (3) Cell Therapy, and (4) Arginine Deprivation Therapy . The Company is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities. The Company also conducts commercial sales of specialty products through its wholly owned subsidiary, Athenex Pharmaceutical Division (“APD”), and 503B products through its wholly owned subsidiary, Athenex Pharma Solutions (“APS”). Significant Risks and Uncertainties The Company has incurred operating losses since its inception and, as a result, as of March 31, 2021 and December 31, 2020 had an accumulated deficit of $738.7 The Company believes that the existing cash and cash equivalents, restricted cash, and short-term investments will enable us to meet our current operational liquidity needs and fund operations into the second half of 2022. The Company has based these estimates on assumptions that may prove to be wrong, and it could spend the available financial resources much faster than expected and need to raise additional funds sooner than anticipated. In February 2021, the Company received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for oral paclitaxel and encequidar (“Oral Paclitaxel”) for the treatment of metastatic breast cancer. The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. In the CRL, the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequelae on the Oral Paclitaxel arm compared with the IV paclitaxel arm in the Phase III study. The FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by blinded independent central review (“BICR”). The FDA stated that the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR. The FDA recommended that Athenex conduct a new adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population in the U.S. The FDA determined that additional risk mitigation strategies to improve toxicity, which may involve dose optimization as well as, or in addition to, exclusion of patients deemed to be at higher risk of toxicity, are required to support potential approval of the NDA. We are working to consider the appropriate next steps in the development of Oral Paclitaxel. We have been preparing for and plan to request a meeting with the FDA and plan to engage in a dialogue on the design and scope of a clinical trial to address the FDA ’s requirements and align on the next steps required to obtain approval. The Company’s ability to potentially commercialize Oral Paclitaxel , and the timing of potential commercialization, is dependent on the discussion with the agency, the Company’s resubmission of its NDA, ultimate FDA approval, and potentially additional capital. The Company is subject to a number of risks similar to other biopharmaceutical companies, including, but not limited to, the lack of available capital; possible failure of preclinical testing or clinical trials, inability to obtain regulatory approval of product candidates; competitors developing new technological innovations; unsuccessful commercialization

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, do not include all of the information the opinion of management, reflect all normal recurring adjustments necessary a fair of the results for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of Athenex, Inc. and those of its subsidiaries in which Athenex, Inc. has a controlling financial interest. Intercompany transactions and balances have been eliminated Results of the Company’s operations for the three months ended March 31, 2021 are not necessarily indicative of the results expected for the year ending December 31, 2021, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (“SEC”) on March 1, 2021. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, measurement of acquired assets and assumed liabilities in business combinations, provision for credit losses, inventory reserves, deferred income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards and other items as appropriate. Actual results could differ from those estimates. Credit Losses The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables and contract assets recorded under Financial Accounting Standards Board (“FASB”) ASC 606, Revenue from Contracts with Customers (“Topic 606”). The Company considers historical collection rates, current financial status of its customers, macroeconomic factors, and other industry-specific factors when evaluating for current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable and contract assets, the Company believes that the carrying value, net of excepted losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments. Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit, invests in highly liquid U.S. treasury notes, commercial paper, and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility, and research and development facility in China, and therefore is subject to foreign currency fluctuation and regulatory uncertainties.

Restricted Cash

Restricted Cash	3 Months Ended
	Mar. 31, 2021
Restricted Cash [Abstract]
Restricted Cash	3. Restricted Cash The Company had a restricted cash balance of $16.5 million as of March 31, 2021 and December 31, 2020 held in a controlled bank account in connection with the Company’s senior secured loan agreement and related security agreements (the “Senior Credit Agreement”) with Oaktree Fund Administration, LLC, as administrative agent, and the lenders party thereto (collectively, “Oaktree”). The

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consist of the following (in thousands): March 31, 2021 December 31, 2020 Raw materials and purchased parts $ 3,054 $ 6,498 Work in progress 1,728 776 Finished goods 21,542 21,572 Total inventories $ 26,324 $ 28,846

Intangible Assets, net

Intangible Assets, net	3 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, net	5. Intangible Assets, net The Company’s identifiable intangible assets, net, consist of the following (in thousands): March 31, 2021 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 12,641 $ 5,745 $ — $ 6,896 Polymed customer list 1,593 1,482 — 111 Polymed technology 3,712 1,754 — 1,958 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 728 — — 728 Effect of currency translation adjustment (211 ) — — (211 ) Total intangible assets, net $ 18,463 $ 8,981 $ — $ 9,482 December 31, 2020 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 12,641 $ 5,157 $ — $ 7,484 Polymed customer list 1,593 1,418 — 175 Polymed technology 3,712 1,685 — 2,027 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 728 — — 728 Effect of currency translation adjustment (196 ) — — (196 ) Total intangibles, net $ 18,478 $ 8,260 $ — $ 10,218 As of March 31, 2021, licenses at cost include an Orascovery license of $0.4 million, licenses purchased from Gland Pharma Limited (“Gland”) of $4.4 The remaining intangible assets were acquired in connection with the acquisitions of Polymed Therapeutics, Inc. (“Polymed”) and Comprehensive Drug Enterprises (“CDE”). Intangible assets are amortized using an economic consumption model over their useful lives. The Polymed customer list and technology are amortized on a straight-line basis over 6 and 12 years, respectively. The CDE in-process research and development, (“IPR&D”), will not be amortized until the related projects are completed. IPR&D is tested annually for impairment, unless conditions exist causing an earlier impairment test (e.g., abandonment of project). The Company recorded no impairments of IPR&D during the three months ended March 31, 2021. The weighted-average useful life for all intangible assets was 7.1 years as of March 31, 2021. The Company recorded The Company’s goodwill balance is the result of prior period acquisitions and is allocated to the Global Supply Chain Platform reporting unit and the Oncology Innovation Platform reporting unit. Changes in goodwill balances reported within the unaudited condensed consolidated balance sheet as of March 31, 2021 are due to the effect of foreign currency on goodwill from acquisitions of subsidiaries that have a functional currency other than USD. During the first quarter of 2021, due to the significant decrease in its market capitalization, the Company evaluated the impact on each of its reporting units to assess whether there was a triggering event requiring it to perform a goodwill impairment test (ASC350-20-35). The Company determined a triggering event occurred and, as such, performed an interim goodwill quantitative impairment test for its reporting units. It also considered certain qualitative factors, such as the Company’s performance, business forecasts, and expansion plans. It reviewed key assumptions, including revisions of projected cash flows and future revenue for reporting units against the results of the annual quantitative impairment test performed during the last quarter of 2020. Using both the income approach and the market approach for its Global Supply Chain Platform and Oncology Innovation Platform, with the discount rate selected considering and capturing the related risk associated with the forecast, the Company compared the fair value of the two reporting units to carrying value. Based on the results, the fair value of each of our reporting units exceeded their carrying value and the goodwill was not impaired. However, there can be no assurances that goodwill will not be impaired in future periods. Estimating the fair value of goodwill requires the use of estimates and significant judgments that are based on a number of factors. These estimates and judgments may not be within the control of the Company and accordingly it is reasonably possible that the judgments and estimates could change in future periods.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements Financial instruments consist of cash and cash equivalents, restricted cash, short-term investments, an available-for-sale equity investment, accounts receivable, accounts payable, accrued liabilities, and debt. Short-term investments and the equity investment are stated at fair value. Cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts. ASC 820, Fair Value Measurements , establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under the ASC 820 are described as follows: Level 1 —Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 —Inputs to the valuation methodology include: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets or liabilities in inactive markets; • Inputs other than quoted prices that are observable for the asset or liability; • Inputs that are derived principally from or corroborated by observable market data by correlation or other means; and • If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3 —Inputs to the valuation methodology are unobservable, supported by little or no market activity, and are significant to the fair value measurement. Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at March 31, 2021 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 5,497 $ 5,497 $ — $ — Short-term investments - certificates of deposit 1,000 — 1,000 — Short-term investments - commercial paper 22,548 — 22,548 — Financial assets included within short-term investments Short-term investments - certificates of deposit 22,769 — 22,769 — Short-term investments - U.S. government bonds 15,000 — 15,000 — Short-term investments - commercial paper 85,185 — 85,185 — Available-for-sale investment 232 232 — — Total assets $ 152,231 $ 5,729 $ 146,502 $ — Fair Value Measurements at December 31, 2020 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 5,615 $ 5,615 $ — $ — Short-term investments - certificates of deposit 4,070 — 4,070 — Short-term investments - U.S. government bonds 5,000 — 5,000 — Short-term investments - commercial paper 34,860 — 34,860 — Financial assets included within short-term investments Short-term investments - certificates of deposit 20,696 — 20,696 — Short-term investments - U.S. government bonds 14,998 — 14,998 — Short-term investments - commercial paper 102,715 — 102,715 — Available-for-sale investment 227 227 — — Total assets $ 188,181 $ 5,842 $ 182,339 $ — The Company classifies its money market funds within Level 1 because it uses quoted market prices to determine their fair value. The Company classifies its commercial paper, corporate notes, certificates of deposit, and U.S. government bonds within Level 2 because it uses quoted prices for similar assets or liabilities in active markets and each has a specified term and all Level 2 inputs are observable for substantially the full term of each instrument. The Company owns 68,000 shares of PharmaEssentia, a company publicly traded on the Taiwan OTC Exchange. As of March 31, 2021 and December 31, 2020, the Company’s investment in PharmaEssentia was valued at the reported closing price on such dates. This investment is classified as a Level 1 investment and is recorded as an available-for-sale investment within short-term investments on the Company’s condensed consolidated balance sheet.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Accrued Expenses	7. Accrued Expenses Accrued expenses consist of the following (in thousands): March 31, December 31, 2021 2020 Accrued wages and benefits $ 7,798 $ 6,720 Accrued selling fees, rebates, and royalties 4,388 9,046 Accrued operating expenses 3,804 3,222 Accrued construction costs 3,421 4,104 Accrued inventory purchases 2,397 3,714 Accrued clinical expenses 2,073 2,949 Accrued tax withholdings 1,863 1,948 Accrued costs for product launch 1,415 1,474 Deferred revenue 1,289 1,147 Accrued R&D licensing fees 266 366 Accrued interest — 3,583 Total accrued expenses $ 28,714 $ 38,273 The accrued construction costs relate to the building of the manufacturing facility in Dunkirk, NY. This amount, plus an additional $0.4 million paid by the Company is expected to be funded by New York State. Therefore, $3.8 million is recorded within prepaid expenses and other current assets on the Company’s condensed consolidated balance sheet as of March 31, 2021

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes The Company did not record a provision for U.S. federal income taxes for the three months ended March 31, 2021 because it expects to generate a loss for the year ending December 31, 2021 and the Company’s net deferred tax assets continue to be fully offset by a valuation allowance. million , on milestone payments in connection with an out-license agreement.

Debt and Lease Obligations

Debt and Lease Obligations	3 Months Ended
	Mar. 31, 2021
Debt And Lease Obligations [Abstract]
Debt and Lease Obligations	9. Debt and Lease Obligations Debt The Company’s debt as of March 31, 2021 and December 31, 2020, consists of the following (in thousands): March 31, December 31, 2021 2020 Current portion of mortgage $ 729 $ 731 Current portion of bank loan 761 764 Current portion of senior secured loan 70 70 Current portion of finance lease obligations 410 445 Current portion of operating lease obligations 3,161 3,185 Long-term portion of finance lease obligations 474 537 Long-term portion of operating lease obligations 5,832 6,355 Chongqing Maliu credit agreement 7,614 7,641 Senior secured loan, net of debt discount and financing fees of $10,822 and $11,601 respectively 139,178 138,399 Total $ 158,229 $ 158,127 Senior Credit Agreement On June 19, 2020 (“Closing Date”), the Company entered into the Senior Credit Agreement with Oaktree to borrow up to $225.0 million in five tranches, with a maturity date of June 19, 2026. Three tranches (“Tranche A”, “Tranche B”, and “Tranche D”) of the term loans with an aggregate principal amount of $150.0 million were drawn by the Company in 2020. One tranche (“Tranche C”) of $25.0 million will be available to the Company from 90 days after the Closing Date through June 20, 2022, subject to the Company’s satisfaction of a certain regulatory milestone; and the last tranche of $50.0 million (“Tranche E”) will be available to the Company from 90 days after the Closing Date through June 19, 2023, also subject to the Company’s satisfaction of a certain commercial milestone. The loan bears interest at a fixed annual rate of 11.0%. The Company allocated the proceeds of the drawn tranches between liability and equity components and the fair value of such equity components, along with the direct costs related to the issuance of the debt were recorded as an offset to long-term debt on the consolidated balance sheets. The debt discount and financing fees are amortized on a straight-line basis, which approximates the effective interest method, over the remaining maturity of the Senior Credit Agreement. The effective interest rate of Tranches A, B and D, including the amortization of debt discount and financing fees amounts to 13.3% annually. The Company is required to make quarterly interest-only payments until June 19, 2022, after which the Company is required to make quarterly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity. Beginning on September 17, 2020, the Company was required to pay a commitment fee on any undrawn commitments equal to 0.6% per annum, payable on each subsequent funding date or the commitment termination date. Prepayments of the loan, in whole or in part, will be subject to early prepayment fee which declines each year until the fourth anniversary date of the Closing Date, after which no prepayment fee is required. Upon the final payment, the Company must also pay an exit fee calculated based on a percentage of the aggregate principal amount of all tranches advanced to the Company, and as of March 31, 2021 and December 31, 2020, the Company has reflected a long-term exit fee liability of $3.0 million within long-term debt and finance lease obligations on the consolidated balance sheet. The Senior Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that were customarily required for similar financings. The Company is subject to certain financial covenants under the Senior Credit Agreement, including (1) a minimum liquidity amount in cash or permitted cash equivalent investments of $20.0 million from the closing date until the date on which the aggregate principal amount of loans outstanding is greater than or equal to $150.0 million (the “First Step-Up Date”), $25.0 million from the First Step-Up Date until the date on which the aggregate principal amount of loans outstanding balance is equal to $225.0 million (the “Second Step-Up Date”), and $30.0 million from the Second Step-up Date until the maturity date; (2) minimum revenue no less than 50% of target revenue beginning with the fiscal quarter ended on December 31, 2020 and with respect to each such subsequent fiscal quarter prior to the revenue covenant termination date; (3) leverage ratio covenant not to exceed 4.50 to 1.00 as of the last day of any fiscal quarter beginning with the first fiscal quarter following the revenue covenant termination date. At March 31, 2021, the Company was in compliance with all applicable debt covenants. Revenue Interest Financing Agreement On August 4, 2020, the Company entered into a Revenue Interest Financing Agreement with Sagard, pursuant to which Sagard agreed to pay the Company $50.0 million to provide funding for the Company’s development and commercialization of Oral Paclitaxel upon receipt of marketing authorization for Oral Paclitaxel by the U.S. FDA for the treatment of metastatic breast cancer. In the event the Company is unable to do so before December 31, 2021, Sagard will have a termination right. In exchange for the Product Payment, the Company agreed to make payments to Sagard equal to 5.0% of its world-wide net sales of Oral Paclitaxel, subject to a hard cap equal to the lesser of 170% of the Product Payment and the Put/Call Price as discussed below and further set forth in the Revenue Interest Financing Agreement. The Company is required to make certain additional payments to Sagard to the extent Sagard has not received Payments equaling at least $20.0 million by September 30, 2024 and at least $50.0 million by August 4, 2026, in the amount of the applicable shortfall, and, subject to the Hard Cap, if Sagard has not received Payments equaling at least $85.0 million by the tenth anniversary of the date the Product Payment is funded, in an amount such that Sagard will have obtained a 6.0% internal rate of return on the Product Payment. The Company’s obligations under the Revenue Interest Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions and subject to an intercreditor agreement with Oaktree as administrative agent for the lenders under our Senior Credit Agreement, by a perfected security interest in (i) accounts receivable arising from net sales of Oral Paclitaxel and (ii) intellectual property that is claiming or covering Oral Paclitaxel itself or any method of using, making or manufacturing Oral Paclitaxel. Credit Agreements, Bank Loan and Mortgage During the second quarter of 2019, the Company entered into a credit agreement which amended the existing partnership agreement with Chongqing Maliu Riverside Development and Investment Co., LTD (“CQ”), for a Renminbi ¥50.0 million (USD $7.7 million at December 31, 2020) line of credit to be used for the construction of the new API plant in China. The Company is required to repay the principal amount with accrued interest within three years after the plant receives the cGMP certification, with 20% of the total loan with accrued interest is due within the first twelve months following receiving the certification, 30% of the total loan with accrued interest due within twenty-four months, and the remaining balance with accrued interest due within thirty-six months. Interest accrues at the three-year loan interest rate by the People’s Bank of China for the same period on the date of the deposit of the full loan amount, which is expected to approximate 4.75% annually. If the Company fails to obtain the cGMP certification within three years upon the acceptance of the plant, it shall return all renovation costs with the accrued interest to CQ in a single transaction within the first ten business days. As of March 31, 2021, the balance due to CQ was $7.6 million. On May 15, 2020, the Company entered into a credit agreement with China Merchants Bank, enabling the Company to draw up to a Renminbi ¥5.0 million (USD $0.8 million at March 31, 2021) during the period through May 14, 2021. The Company drew the entire available credit in July 2020. This loan has a maturity date of May 14, 2021 and bears interest at a fixed rate of 4.35% annually. The Company is required to pay the outstanding principal and all accrued interest at maturity. The mortgage payments, assumed in connection with the acquisition of CDE, extend through December 31, 2021. Lease Obligations The Company has operating leases for office and manufacturing facilities in several locations in the U.S., Asia, and Latin America and has three finance leases for manufacturing equipment used in its facilities near Buffalo, NY. The components of lease expense are as follows (in thousands): Three Months Ended March 31, 2021 2020 Operating lease cost 746 $ 755 Finance lease cost: Amortization of assets 75 34 Interest on lease liabilities 24 6 Total net lease cost $ 845 $ 795 The Company has elected to exclude short-term leases from its operating lease right-of-use (“ROU”) assets and lease liabilities. Lease costs for short-term leases were not material to the financial statements for the three months ended March 31, 2021 and 2020. Variable lease costs for the three months ended March 31, 2021 were not material to the financial statements. Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): March 31, 2021 December 31, 2020 Finance leases: Property and equipment, at cost $ 1,535 $ 1,535 Accumulated amortization, net (422 ) (347 ) Property and equipment, net $ 1,113 $ 1,188 Current obligations of finance leases $ 410 $ 445 Long-term portion of finance leases 474 537 Total finance lease obligations $ 884 $ 982 Weighted average remaining lease term (in years): Operating leases 3.96 4.23 Finance leases 3.06 3.40 Weighted average discount rate: Operating leases 12.8 % 12.8 % Finance leases 10.8 % 10.4 % Supplemental cash flow information related to leases is as follows (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Cash paid for amount included in the measurements of lease liabilities: Operating cash flows from operating leases $ (979 ) $ (820 ) Operating cash flows from finance leases (24 ) (6 ) Financing cash flows from finance leases (98 ) (47 ) ROU assets derecognized from modification of operating lease obligations — (468 ) ROU assets recognized in exchange for operating lease obligations $ — $ 353 Future minimum payments and maturities of leases is as follows (in thousands): Year ending December 31: Operating Leases Finance Leases 2021 (remaining nine months) $ 2,577 $ 351 2022 2,918 275 2023 2,096 248 2024 2,002 157 2025 1,472 — Thereafter 478 — Total lease payments 11,543 1,031 Less: Imputed interest (2,550 ) (147 ) Total lease obligations 8,993 884 Less: Current obligations (3,161 ) (410 ) Long-term lease obligations $ 5,832 $ 474 Pursuant to the public-private partnership agreements with the State of New York, the Company will rent the manufacturing facilities in Dunkirk, NY. The facility is in the final stage of completion. However, no lease term had commenced as of March 31, 2021, as it was not yet operational and the Company could not direct the use of the facility. No lease costs were incurred related to the manufacturing facility during the three-month period ended March 31, 2021. On January 5, 2021, Chongqing Sintaho Pharmaceuticals Co., Ltd. (“CQ Sintaho”), a subsidiary of the Company in China, entered into a lease agreement with Chongqing International Biological City Development & Investment Co., Ltd (“CQ D&I”). Under the lease agreement, the provisions of which are consistent with those agreed upon in the 2015 Agreement, CQ Sintaho leased the newly constructed API facility, or Sintaho API Facility, of 34,517 square meters rent-free, for the first 10-year term, with an option to extend the lease for an additional 10-year term, during which, if CQ Sintaho is profitable, it will pay a monthly rent of 5 RMB per square meter of space occupied. The Company determined the lease had commenced as of March 31, 2021, as it was operational and CQ Sintaho could direct the use of the facility. The Company also evaluated the probability of exercising the renewal and purchase options, and determined that it is not reasonably certain whether it will exercise those options. Therefore, the lease term is comprised only of the rent-free period and the recognition of the right-of-use asset and liability did not have a significant effect on the Company’s consolidated financial statements. The Company exercises judgment in determining the discount rate used to measure the lease liabilities. When rates are not implicit within an operating lease, the Company uses its incremental borrowing rate as its discount rate, which is based on yield trends in the biotechnology and healthcare industry and debt instruments held by the Company with stated interest rates. The Company re-assesses its incremental borrowing rate when new leases arise, or existing leases are modified.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions During the three months ended March 31, 2021 and 2020, the Company entered into transactions with individuals and companies that have financial interests in the Company. Related party transactions included the following: a. In June 2018, the Company entered into two in-licensing agreements with Avalon BioMedical (Management) Limited (“Avalon”) wherein the Company obtained certain IP from Avalon to develop and commercialize the underlying products. Under these agreements the Company is required to pay upfront fees and future milestone payments and sales-based royalties. In June 2019, the Company entered into an agreement whereby Avalon would hold a 90% ownership interest and the Company would hold a 10% ownership interest of the newly formed entity under the name Nuwagen Limited (“Nuwagen”), incorporated under the laws of Hong Kong. Nuwagen is principally engaged in the development and commercialization of herbal medicine products for metabolic, endocrine, and other related indications. The Company contributed nonmonetary assets in exchange for the 10% ownership interest. In July 2020, the transaction closed. The activities of Nuwagen were not material to the financial statements for the three months ended March 31, 2021. b. The Company earns licensing revenue from PharmaEssentia, an entity in which the Company has an investment classified as available-for-sale (see Note 6— Fair Value Measurements In September 2020, Axis Therapeutics Limited (“Axis”), a majority-owned subsidiary of the Company, entered into a collaboration agreement with PharmaEssentia, pursuant to which Axis granted to PharmaEssensia an exclusive, non-transferrable and revocable sublicense of TCR-engineered T Cell therapy for the development of the technology in Taiwan. Axis received license fee of $1.0 million, net of $0.3 million withholding tax, in the fourth quarter of 2020. This amount was recorded as deferred revenue as of March 31, 2021. c. The Company receives certain clinical development services from ZenRx Limited and its affiliate (collectively, “ZenRx”), a company for which one of the Company’s executive officers serves on the board of directors. In connection with such services, the Company made payments to ZenRx of d . Certain family members of executives perform consulting services for the Company. Such services were not significant to the condensed consolidated financial statements.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation Common Stock Option Plans The Company has four equity compensation plans, adopted in 2017, 2013, 2007 and 2004 (the “Plans”) which, taken together, authorize the grant of up to 16,000,000 shares of common stock to employees, directors, and consultants. On May 23, 2019, the board of directors approved the amendment and restatement of the 2017 Omnibus Incentive Plan (the “2017 Plan”, which increases the number of shares available for issuance under the 2017 Plan by up to 3,500,000 shares, which was approved by the Company’s stockholders at the Company’s 2020 annual meeting of stockholders . On April 26, 2021, the board of directors approved an amendment to the 2017 Plan, which increases the number of shares available for issuance under the 2017 Plan by 5,000,000 shares, subject to the approval of the Company’s stockholders at the Company’s 2021 annual meeting of stockholders. The Company also has an employee stock purchase plan, the 2017 Employee Stock Purchase Plan (the “ESPP”), adopted on June 14, 2017, which authorizes the issuance of up to 1,000,000 shares of common stock for future issuances to eligible employees. Stock Options The total fair value of stock options vested and recorded as compensation expense during the three months ended March 31, 2021 and 2020 was $2.2 million and $1.9 million, respectively. As of March 31, 2021, $16.5 million of unrecognized cost related to non-vested stock options was expected to be recognized over a weighted-average period of approximately 1.8 years. T he total intrinsic value of options exercised was approximately $0.2 million and $0.8 million for the three months ended March 31, 2021 and 2020, respectively The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (aggregate intrinsic value in thousands): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2020 12,496,888 $ 9.26 5.42 $ 22,463 Granted 20,000 11.90 — — Exercised (119,425 ) 7.10 — — Forfeited and expired (32,830 ) 12.92 — — Outstanding at March 31, 2021 12,364,633 $ 9.28 5.20 $ — Vested and exercisable at March 31, 2021 9,504,028 $ 8.21 4.28 $ — The Company determines the fair value of stock-based awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding several highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Three Months Ended March 31, 2021 2020 Weighted average grant date fair value $ 7.40 $ 7.32 Expected dividend yield — % — % Expected stock price volatility 68 % 67 % Risk-free interest rate 1.37 % 0.75 % Expected life of options (in years) 6.3 5.0 Restricted Stock Awards No million and $0.4 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, $0.3 million of unrecognized cost related to non-vested restricted stock awards were expected to be recognized over a weighted-average period of approximately 1.4 years. Employee Stock Purchase Plan The ESPP is available to eligible employees (as defined in the plan document). Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from December 1, 2020 to May 31, 2021. The Company expects to offer six-month offering periods after the current period. The ESPP reserved 1,000,000 shares of common stock for issuance under the ESPP. Stock-based compensation related to the ESPP amounted to $0.1 million for each of the three months ended March 31, 2021 and 2020. Stock-Based Compensation Cost The components of stock-based compensation and the amounts recorded within cost of sales, research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 2020 Stock options $ 2,205 $ 1,864 Restricted stock expense 29 397 Employee stock purchase plan 46 70 Total stock-based compensation expense $ 2,280 $ 2,331 Cost of sales $ 56 $ 54 Research and development expenses 601 946 Selling, general, and administrative expenses 1,623 1,331 Total stock-based compensation expense $ 2,280 $ 2,331

Net Loss per Share Attributable

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Athenex, Inc. Common Stockholders	12. Net Loss per Share Attributable to Athenex, Inc. Common Stockholders Basic net loss per share is calculated by dividing net loss attributable to Athenex, Inc. common stockholders by the weighted-average number of common shares issued, outstanding, and vested during the period. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents for the period using the treasury-stock method. For the purposes of this calculation, warrants to purchase common stock and stock options are considered common stock equivalents but are only included in the calculation of diluted net loss per share when their effect is dilutive. The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2021 2020 Stock options and other common stock equivalents 13,899,191 11,347,475 Unvested restricted shares 22,500 105,000 Total potential dilutive shares 13,921,691 11,452,475

Business Segment, Geographic, a

Business Segment, Geographic, and Concentration Risk Information	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Business Segment, Geographic, and Concentration Risk Information	13. Business Segment, Geographic, and Concentration Risk Information The Company has three operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue (only applicable to two reportable segments). Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. Consequently, the Company has concluded each operating segment to be a reportable segment. The Company’s operating segments are as follows: Oncology Innovation Platform— This operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. It focuses specifically on Orascovery and Src Kinase Inhibition research platforms, cell therapy programs and arginine deprivation therapy. Global Supply Chain Platform — This operating segment includes APS and Polymed and the construction of the manufacturing facilities in Chongqing, China, and Dunkirk, NY. APS is a manufacturing company that supplies sterile injectable drugs to hospital pharmacies across the U.S. APS manufactures products under Section 503B of the Compounding Quality Act within the Federal Food, Drug & Cosmetic Act (“FDCA”). Additionally, APS provides products for the development and manufacturing of the Company’s proprietary drug candidates as well as providing the Company with a cGMP analytical services function. Polymed is primarily in the business of marketing and selling API in North America, Europe, and Asia from its locations in Texas and China. Polymed also develops new compounds and processing techniques and is in the final phase of completion of the new API manufacturing facility in Chongqing, China. Commercial Platform — This operating segment includes APD and Athenex Oncology, which focus on the manufacturing, distribution, and sales of specialty pharmaceuticals and the pre-launch commercial activities for the Company’s proprietary drugs, respectively. This segment provides services and products to external customers based mainly in the U.S. The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the U.S., Taiwan, Hong Kong, mainland China, the United Kingdom, and Latin America. The Global Supply Chain Platform segment operates and holds long-lived assets located in the U.S. and China. The Commercial Platform segment operates and holds long-lived assets located in the U.S. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer. Segment information is as follows (in thousands): Three Months Ended March 31, 2021 2020 Total revenue: Oncology Innovation Platform $ 20,665 $ 28,387 Global Supply Chain Platform 8,207 3,714 Commercial Platform 13,259 15,542 Total revenue for reportable segments 42,131 47,643 Intersegment revenue (1,106 ) (708 ) Total consolidated revenue $ 41,025 $ 46,935 Intersegment revenue eliminated in the above table reflects $0.6 million in sales from the Global Supply Chain Platform to the Commercial Platform and $0.5 million in sales from the Global Supply Chain Platform to the Oncology Innovation Platform (in thousands). Three Months Ended March 31, 2021 2020 Total revenue by product group: License fees $ 20,500 $ 28,381 Commercial product sales 18,061 17,502 API sales 1,868 1,022 Contract manufacturing revenue 430 23 Other revenue 166 7 Total consolidated revenue $ 41,025 $ 46,935 Intersegment revenue is recognized by the selling segment when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger (in thousands). Three Months Ended March 31, 2021 2020 Net loss attributable to Athenex, Inc.: Oncology Innovation Platform $ (5,441 ) $ (958 ) Global Supply Chain Platform (3,682 ) (5,986 ) Commercial Platform (15,927 ) (12,485 ) Total consolidated net loss attributable to Athenex, Inc. $ (25,050 ) $ (19,429 ) Three Months Ended March 31, 2021 2020 Total depreciation and amortization: Oncology Innovation Platform $ 207 $ 175 Global Supply Chain Platform 523 496 Commercial Platform 544 415 Total consolidated depreciation and amortization $ 1,274 $ 1,086 March 31, December 31, 2021 2020 Total assets: Oncology Innovation Platform $ 199,741 $ 234,153 Global Supply Chain Platform 101,621 99,087 Commercial Platform 48,294 51,089 Total consolidated assets $ 349,656 $ 384,329 Three Months Ended March 31, 2021 2020 Total revenue: United States $ 38,645 $ 17,522 China 205 28,513 Other foreign countries 2,175 900 Total consolidated revenue $ 41,025 $ 46,935 March 31, December 31, 2021 2020 Total property and equipment, net: United States $ 20,902 $ 15,511 China 20,876 18,877 Total consolidated property and equipment, net $ 41,778 $ 34,388 Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment. Three Months Ended March 31, 2021 2020 Percentage of total revenue by customer: Customer A 49 % 0 % Customer B 11 % 9 % Customer C 9 % 11 % Customer D 9 % 7 % Customer E 0 % 60 % March 31, December 31, 2021 2020 Percentage of total accounts receivable by customer: Customer A 36 % 33 % Customer B 30 % 24 % Customer C 10 % 16 % Customer D 0 % 6 %

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue Recognition	14. Revenue Recognition The Company records revenue in accordance with ASC, Topic 606 “ Revenue from Contracts with Customers .” Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the entity performs the following five steps: (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Below is a description of principal activities – separated by reportable segments – from which the Company generates its revenue . 1. Oncology Innovation Platform The Company out-licenses certain of its IP to other pharmaceutical companies in specific territories that allow the customer to use, develop, commercialize, or otherwise exploit the licensed IP. In accordance with Topic 606, the Company analyzes the contracts to identify its performance obligations within the contract. Most of the Company’s out-license arrangements contain multiple performance obligations and variable pricing. After the performance obligations are identified, the Company determines the transaction price, which generally includes upfront fees, milestone payments related to the achievement of developmental, regulatory, or commercial goals, and royalty payments on net sales of licensed products. The Company considers whether the transaction price is fixed or variable, and whether such consideration is subject to return. Variable consideration is only included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. If any portion of the transaction price is constrained, it is excluded from the transaction price until the constraint no longer exists. The Company then allocates the transaction price to the performance obligation to which the consideration is related. Where a portion of the transaction price is received and allocated to continuing performance obligations under the terms of the arrangement, it is recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied. The Company’s contracts may contain one or multiple promises, including the license of IP and development services. The licensed IP is capable of being distinct from the other performance obligations identified in the contract and is distinct within the context of the contract, as upon transfer of the IP, the customer is able to use and benefit from it, and the customer could obtain the development services from other parties. The Company also considers the economic and regulatory characteristics of the licensed IP and other promises in the contract to determine if it is a distinct performance obligation. The Company considers if the IP is modified or enhanced by other performance obligations through the life of the agreement and whether the customer is contractually or practically required to use updated IP. The IP licensed by the Company has been determined to be functional IP. The IP is not modified during the license period and therefore, the Company recognizes revenues from any portion of the transaction price allocated to the licensed IP when the license is transferred to the customer and they can benefit from the right to use the IP. For the three-month period ended March 31, 2021, the Company recognized license revenue of $20.5 million, of which $20.0 million was recognized upon the achievement of the first commercial milestone pursuant to the 2017 Almirall out-license arrangement upon the launch of Klisyri in the U.S., and $0.5 million was recognized for an upfront fee upon transferring IP to the customer upon execution of the second amendment to the 2011 PharmaEssentia license agreement. Under the collaboration agreement between Axis Therapeutics and PharmaEssentia, the Company received $1.0 million, net of $0.3 million withholding tax, of upfront fees allocated to its performance obligation to deliver functional IP to the Customer. As of March 31, 2021, the Company had not satisfied this performance obligation by delivering the license with the data necessary for the customer to benefit from the right to use the IP and, therefore, the amount was recorded as deferred revenue. Other performance obligations included in most of the Company’s out-licensing agreements include performing development services to reach clinical and regulatory milestone events. The Company satisfies these performance obligations at a point-in-time, because the customer does not simultaneously receive and consume the benefits as the development occurs, the development does not create or enhance an asset controlled by the customer, and the development does not create an asset with no alternative use. The Company considers milestone payments to be variable consideration measured using the most likely amount method, as the entitlement to the consideration is contingent on the occurrence or nonoccurrence of future events. The Company allocates each variable milestone payment to the associated milestone performance obligation, as the variable payment relates directly to the Company’s efforts to satisfy the performance obligation and such allocation depicts the amount of consideration to which the Company expects to be entitled for satisfying the corresponding performance obligation. The Company re-evaluates the probability of achievement of such performance obligations and any related constraint and adjusts its estimate of the transaction price as appropriate. To date, no amounts have been constrained in the initial or subsequent assessments of the transaction price. The Company did not recognize revenue from other performance obligations included in the Company’s out-licensing agreements during the three month periods ended March 31, 2021 and 2020. Certain out-license agreements include performance obligations to manufacture and provide drug product in the future for commercial sale when the licensed product is approved. For the commercial, sales-based royalties, the consideration is predominantly related to the licensed IP and is contingent on the customer’s subsequent sales to another commercial customer. Consequently, the sales- or usage-based royalty exception would apply. Revenue will be recognized for the commercial, sales-based milestones as the underlying sales occur. The Company exercises significant judgment when identifying distinct performance obligations within its out-license arrangements, determining the transaction price, which often includes both fixed and variable considerations, and allocating the transaction price to the proper performance obligation. The Company did not use any other significant judgments related to out-licensing revenue during the . 2. Global Supply Chain Platform The Company’s Global Supply Chain Platform manufactures API for use internally in its research and development activities as well as its clinical studies, and for sale to pharmaceutical customers globally. The Company generates additional revenue on this platform, by providing small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies and selling pharmaceutical products under 503B regulations set forth by the U.S. FDA. Revenue earned by the Global Supply Platform is recognized when the Company has satisfied its performance obligation, which is the shipment or the delivery of drug products. The underlying contracts for these sales are generally purchase orders and the Company recognizes revenue at a point-in-time. Any remaining performance obligations related to product sales are the result of customer deposits and are reflected in the deferred revenue contract liability balance. 3. Commercial Platform The Company’s Commercial Platform generates revenue by distributing specialty products through independent pharmaceutical wholesalers. The wholesalers then sell to an end-user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end-user and the Company. Upon the sale by the wholesaler to the end-user, the wholesaler will chargeback the difference, if any, between the original list price and price at which the product was sold to the end-user. The Company also offers cash discounts, which approximate 2.3% of the gross sales price, as an incentive for prompt customer payment, and, consistent with industry practice, the Company’s return policy permits customers to return products within a window of time before and after the expiration of product dating. Further, the Company offers contractual allowances, generally in the form of rebates or administrative fees, to certain wholesale customers, group purchasing organizations (“GPOs”), and end-user customers, consistent with pharmaceutical industry practices. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, GPO allowances, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). As of March 31, 2021, and December 31, 2020, the Company’s total provision for chargebacks and other deductions included as a reduction of accounts receivable totaled $17.3 million and $12.6 million, respectively. The Company’s total provision for chargebacks and other revenue deductions was $25.6 million, and $24.9 million for the three months ended March 31, 2021, and 2020, respectively. The Company exercises significant judgment in its estimates of the variable transaction price at the time of the sale and recognizes revenue when the performance obligation is satisfied. Factors that determine the final net transaction price include chargebacks, fees for service, cash discounts, rebates, returns, warranties, and other factors. The Company estimates all of these variables based on historical data obtained from previous sales finalized with the end-user customer on a product-by-product basis. At the time of sale, revenue is recorded net of each of these deductions. Through the normal course of business, the wholesaler will sell the product to the end-user, determining the actual chargeback, return products, and take advantage of cash discounts, charge fees for services, and claim warranties on products. The final transaction price per product is compared to the initial estimated net sale price and reviewed for accuracy. The final prices and other factors are immediately included in the Company’s historical data from which it will estimate the transaction price for future sales. The underlying contracts for these sales are generally purchase orders including a single performance obligation, generally the shipment or delivery of products and the Company recognizes this revenue at a point-in-time. Disaggregation of revenue The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer. For the Three Months Ended March 31, 2021 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ 20,157 $ 5,229 $ 13,259 $ 38,645 China 8 197 — 205 Other foreign countries 500 1,675 — 2,175 Total revenue $ 20,665 $ 7,101 $ 13,259 $ 41,025 For the Three Months Ended March 31, 2020 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total China $ 28,308 $ 205 $ — $ 28,513 United States — 1,980 15,542 17,522 Other foreign countries 79 821 — 900 Total revenue $ 28,387 $ 3,006 $ 15,542 $ 46,935 The Company also disaggregates its revenue by product group which can be found in Note 13 – Business Segment, Geographic, and Concentration Risk Information Contract balances The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers. March 31, 2021 December 31, 2020 (In Thousands) Accounts receivable, gross $ 46,935 $ 45,792 Chargebacks and other deductions (17,264 ) (12,552 ) Provision for credit losses (9,482 ) (9,637 ) Accounts receivable, net $ 20,189 $ 23,603 Deferred revenue 1,289 1,147 Total contract liabilities $ 1,289 $ 1,147 The following tables illustrate accounts receivable and contract asset balances by reportable segments. March 31, 2021 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 9,167 $ 3,589 $ 34,179 $ 46,935 Chargebacks and other deductions — — (17,264 ) (17,264 ) Provision for credit losses (8,919 ) (138 ) (425 ) (9,482 ) Accounts receivable, net 248 3,451 16,490 20,189 December 31, 2020 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 10,783 $ 4,074 $ 30,935 $ 45,792 Chargebacks and other deductions — (1 ) (12,551 ) (12,552 ) Provision for credit losses (8,919 ) (164 ) (554 ) (9,637 ) Accounts receivable, net $ 1,864 $ 3,909 $ 17,830 $ 23,603 As of March 31, 2021 and December 31, 2020, the deferred revenue balances There were no other material changes to contract balances during the three months ended March 31, 2021.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Future minimum payments under the non-cancelable operating leases consists of the following as of March 31, 2021 (in thousands): Year ending December 31: Minimum payments 2021 (remaining nine months) $ 2,577 2022 2,918 2023 2,096 2024 2,002 2025 1,472 Thereafter 478 $ 11,543 Legal Proceedings Following our receipt of the CRL in February 2021 and the subsequent decline of the market price of the Company’s common stock, two purported securities class action lawsuits were filed in the U.S. District Court for the Western District of New York on March 3, 2021 and March 22, 2021, respectively, against the Company and certain members of its management team seeking to recover damages for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaints generally allege that between August 7, 2019 and February 26, 2021 (the purported class period), the Company and the individual defendants made materially false and misleading statements regarding the Company's business in connection with the Company’s development of Oral Paclitaxel for the treatment of metastatic breast cancer and the likelihood of FDA approval, and that the plaintiffs suffered losses when the Company’s stock price dropped after its announcement on February 26, 2021 regarding receipt of the CRL. The complaints seek class certification, damages, fees, costs, and expenses. The defendants expect that these two lawsuits will be consolidated and a lead plaintiff appointed in the coming months. Additional similar lawsuits might be filed. The Company and the individual defendants believe that the claims in these lawsuits are without merit, and the Company has not recorded a liability related to this shareholder class action lawsuit as the risk of loss is remote. The Company and the individual defendants intend to vigorously defend against these claims but there can be no assurances as to the outcome.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Event	16. Subsequent Event On May 4, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Kuur Therapeutics, Inc., a Delaware corporation (“Kuur”). Kuur is a leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies. Pursuant to the terms of the Merger Agreement, the Company will pay $70.0 million upfront to Kuur shareholders and its former employees and directors, comprised primarily of equity in the Company’s common stock. Additionally, Kuur shareholders and its former employees and directors are eligible to receive up to $115.0 million of milestone payments, which may be paid, at the Company’s sole discretion, in either cash or additional common stock of the Company (or a combination of both). The Company believes the acquisition strategically combines its TCR program with the groundbreaking NKT cell platform to provide a solution that may address some of the known limitations associated with the first generation of cell therapy treatments focused on autologous CAR-T. Due to the recency of the Merger Agreement, the Company has not yet completed its assessment of the fair value of the assets acquired, the liabilities assumed and the contingent considerations. The Company will account for this in accordance with ASC 805, Business Combinations, and its evaluation the effect on its consolidated financial statements during the second quarter of 2021.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, do not include all of the information the opinion of management, reflect all normal recurring adjustments necessary a fair of the results for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of Athenex, Inc. and those of its subsidiaries in which Athenex, Inc. has a controlling financial interest. Intercompany transactions and balances have been eliminated Results of the Company’s operations for the three months ended March 31, 2021 are not necessarily indicative of the results expected for the year ending December 31, 2021, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (“SEC”) on March 1, 2021.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, measurement of acquired assets and assumed liabilities in business combinations, provision for credit losses, inventory reserves, deferred income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards and other items as appropriate. Actual results could differ from those estimates.
Credit Losses	Credit Losses The Company estimates and records a provision for its expected credit losses related to its financial instruments, including its trade receivables and contract assets recorded under Financial Accounting Standards Board (“FASB”) ASC 606, Revenue from Contracts with Customers (“Topic 606”). The Company considers historical collection rates, current financial status of its customers, macroeconomic factors, and other industry-specific factors when evaluating for current expected credit losses. Forward-looking information is also considered in the evaluation of current expected credit losses. However, because of the short time to the expected receipt of accounts receivable and contract assets, the Company believes that the carrying value, net of excepted losses, approximates fair value and therefore, relies more on historical and current analysis of such financial instruments.
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit, invests in highly liquid U.S. treasury notes, commercial paper, and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility, and research and development facility in China, and therefore is subject to foreign currency fluctuation and regulatory uncertainties.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands): March 31, 2021 December 31, 2020 Raw materials and purchased parts $ 3,054 $ 6,498 Work in progress 1,728 776 Finished goods 21,542 21,572 Total inventories $ 26,324 $ 28,846

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Identifiable Intangible Asset, Net	The Company’s identifiable intangible assets, net, consist of the following (in thousands): March 31, 2021 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 12,641 $ 5,745 $ — $ 6,896 Polymed customer list 1,593 1,482 — 111 Polymed technology 3,712 1,754 — 1,958 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 728 — — 728 Effect of currency translation adjustment (211 ) — — (211 ) Total intangible assets, net $ 18,463 $ 8,981 $ — $ 9,482 December 31, 2020 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 12,641 $ 5,157 $ — $ 7,484 Polymed customer list 1,593 1,418 — 175 Polymed technology 3,712 1,685 — 2,027 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 728 — — 728 Effect of currency translation adjustment (196 ) — — (196 ) Total intangibles, net $ 18,478 $ 8,260 $ — $ 10,218

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at March 31, 2021 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 5,497 $ 5,497 $ — $ — Short-term investments - certificates of deposit 1,000 — 1,000 — Short-term investments - commercial paper 22,548 — 22,548 — Financial assets included within short-term investments Short-term investments - certificates of deposit 22,769 — 22,769 — Short-term investments - U.S. government bonds 15,000 — 15,000 — Short-term investments - commercial paper 85,185 — 85,185 — Available-for-sale investment 232 232 — — Total assets $ 152,231 $ 5,729 $ 146,502 $ — Fair Value Measurements at December 31, 2020 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 5,615 $ 5,615 $ — $ — Short-term investments - certificates of deposit 4,070 — 4,070 — Short-term investments - U.S. government bonds 5,000 — 5,000 — Short-term investments - commercial paper 34,860 — 34,860 — Financial assets included within short-term investments Short-term investments - certificates of deposit 20,696 — 20,696 — Short-term investments - U.S. government bonds 14,998 — 14,998 — Short-term investments - commercial paper 102,715 — 102,715 — Available-for-sale investment 227 227 — — Total assets $ 188,181 $ 5,842 $ 182,339 $ —

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): March 31, December 31, 2021 2020 Accrued wages and benefits $ 7,798 $ 6,720 Accrued selling fees, rebates, and royalties 4,388 9,046 Accrued operating expenses 3,804 3,222 Accrued construction costs 3,421 4,104 Accrued inventory purchases 2,397 3,714 Accrued clinical expenses 2,073 2,949 Accrued tax withholdings 1,863 1,948 Accrued costs for product launch 1,415 1,474 Deferred revenue 1,289 1,147 Accrued R&D licensing fees 266 366 Accrued interest — 3,583 Total accrued expenses $ 28,714 $ 38,273

Debt and Lease Obligations (Tab

Debt and Lease Obligations (Tables)	3 Months Ended
	Mar. 31, 2021
Debt And Lease Obligations [Abstract]
Schedule of Debt	The Company’s debt as of March 31, 2021 and December 31, 2020, consists of the following (in thousands): March 31, December 31, 2021 2020 Current portion of mortgage $ 729 $ 731 Current portion of bank loan 761 764 Current portion of senior secured loan 70 70 Current portion of finance lease obligations 410 445 Current portion of operating lease obligations 3,161 3,185 Long-term portion of finance lease obligations 474 537 Long-term portion of operating lease obligations 5,832 6,355 Chongqing Maliu credit agreement 7,614 7,641 Senior secured loan, net of debt discount and financing fees of $10,822 and $11,601 respectively 139,178 138,399 Total $ 158,229 $ 158,127
Summary of Components of Lease Expense	The components of lease expense are as follows (in thousands): Three Months Ended March 31, 2021 2020 Operating lease cost 746 $ 755 Finance lease cost: Amortization of assets 75 34 Interest on lease liabilities 24 6 Total net lease cost $ 845 $ 795
Schedule of Supplemental Balance Sheet Information Related to Leases of Debt	Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): March 31, 2021 December 31, 2020 Finance leases: Property and equipment, at cost $ 1,535 $ 1,535 Accumulated amortization, net (422 ) (347 ) Property and equipment, net $ 1,113 $ 1,188 Current obligations of finance leases $ 410 $ 445 Long-term portion of finance leases 474 537 Total finance lease obligations $ 884 $ 982 Weighted average remaining lease term (in years): Operating leases 3.96 4.23 Finance leases 3.06 3.40 Weighted average discount rate: Operating leases 12.8 % 12.8 % Finance leases 10.8 % 10.4 %
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases is as follows (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Cash paid for amount included in the measurements of lease liabilities: Operating cash flows from operating leases $ (979 ) $ (820 ) Operating cash flows from finance leases (24 ) (6 ) Financing cash flows from finance leases (98 ) (47 ) ROU assets derecognized from modification of operating lease obligations — (468 ) ROU assets recognized in exchange for operating lease obligations $ — $ 353
Schedule of Future Minimum Payments and Maturities of Leases	Future minimum payments and maturities of leases is as follows (in thousands): Year ending December 31: Operating Leases Finance Leases 2021 (remaining nine months) $ 2,577 $ 351 2022 2,918 275 2023 2,096 248 2024 2,002 157 2025 1,472 — Thereafter 478 — Total lease payments 11,543 1,031 Less: Imputed interest (2,550 ) (147 ) Total lease obligations 8,993 884 Less: Current obligations (3,161 ) (410 ) Long-term lease obligations $ 5,832 $ 474

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (aggregate intrinsic value in thousands): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2020 12,496,888 $ 9.26 5.42 $ 22,463 Granted 20,000 11.90 — — Exercised (119,425 ) 7.10 — — Forfeited and expired (32,830 ) 12.92 — — Outstanding at March 31, 2021 12,364,633 $ 9.28 5.20 $ — Vested and exercisable at March 31, 2021 9,504,028 $ 8.21 4.28 $ —
Schedule of Weighted-Average Assumptions Used as Inputs to Black-Scholes Option Pricing Model	The Company determines the fair value of stock-based awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding several highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Three Months Ended March 31, 2021 2020 Weighted average grant date fair value $ 7.40 $ 7.32 Expected dividend yield — % — % Expected stock price volatility 68 % 67 % Risk-free interest rate 1.37 % 0.75 % Expected life of options (in years) 6.3 5.0
Schedule of Stock-Based Compensation Cost	The components of stock-based compensation and the amounts recorded within cost of sales, research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 2020 Stock options $ 2,205 $ 1,864 Restricted stock expense 29 397 Employee stock purchase plan 46 70 Total stock-based compensation expense $ 2,280 $ 2,331 Cost of sales $ 56 $ 54 Research and development expenses 601 946 Selling, general, and administrative expenses 1,623 1,331 Total stock-based compensation expense $ 2,280 $ 2,331

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2021 2020 Stock options and other common stock equivalents 13,899,191 11,347,475 Unvested restricted shares 22,500 105,000 Total potential dilutive shares 13,921,691 11,452,475

Business Segment, Geographic,_2

Business Segment, Geographic, and Concentration Risk Information (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Summary of Revenue by Segments	Segment information is as follows (in thousands): Three Months Ended March 31, 2021 2020 Total revenue: Oncology Innovation Platform $ 20,665 $ 28,387 Global Supply Chain Platform 8,207 3,714 Commercial Platform 13,259 15,542 Total revenue for reportable segments 42,131 47,643 Intersegment revenue (1,106 ) (708 ) Total consolidated revenue $ 41,025 $ 46,935
Summary of Revenue by Product Group	Three Months Ended March 31, 2021 2020 Total revenue by product group: License fees $ 20,500 $ 28,381 Commercial product sales 18,061 17,502 API sales 1,868 1,022 Contract manufacturing revenue 430 23 Other revenue 166 7 Total consolidated revenue $ 41,025 $ 46,935
Summary of Segment Information	Three Months Ended March 31, 2021 2020 Net loss attributable to Athenex, Inc.: Oncology Innovation Platform $ (5,441 ) $ (958 ) Global Supply Chain Platform (3,682 ) (5,986 ) Commercial Platform (15,927 ) (12,485 ) Total consolidated net loss attributable to Athenex, Inc. $ (25,050 ) $ (19,429 )
Summary of Depreciation, Amortization and Assets by Segment	Three Months Ended March 31, 2021 2020 Total depreciation and amortization: Oncology Innovation Platform $ 207 $ 175 Global Supply Chain Platform 523 496 Commercial Platform 544 415 Total consolidated depreciation and amortization $ 1,274 $ 1,086 March 31, December 31, 2021 2020 Total assets: Oncology Innovation Platform $ 199,741 $ 234,153 Global Supply Chain Platform 101,621 99,087 Commercial Platform 48,294 51,089 Total consolidated assets $ 349,656 $ 384,329
Summary of Revenue by Geographical Segment	Three Months Ended March 31, 2021 2020 Total revenue: United States $ 38,645 $ 17,522 China 205 28,513 Other foreign countries 2,175 900 Total consolidated revenue $ 41,025 $ 46,935
Summary of Property and Equipment by Geographical Segment	March 31, December 31, 2021 2020 Total property and equipment, net: United States $ 20,902 $ 15,511 China 20,876 18,877 Total consolidated property and equipment, net $ 41,778 $ 34,388
Summary of Customer Revenue and Accounts Receivable Concentration	Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment. Three Months Ended March 31, 2021 2020 Percentage of total revenue by customer: Customer A 49 % 0 % Customer B 11 % 9 % Customer C 9 % 11 % Customer D 9 % 7 % Customer E 0 % 60 % March 31, December 31, 2021 2020 Percentage of total accounts receivable by customer: Customer A 36 % 33 % Customer B 30 % 24 % Customer C 10 % 16 % Customer D 0 % 6 %

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer	The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer. For the Three Months Ended March 31, 2021 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ 20,157 $ 5,229 $ 13,259 $ 38,645 China 8 197 — 205 Other foreign countries 500 1,675 — 2,175 Total revenue $ 20,665 $ 7,101 $ 13,259 $ 41,025 For the Three Months Ended March 31, 2020 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total China $ 28,308 $ 205 $ — $ 28,513 United States — 1,980 15,542 17,522 Other foreign countries 79 821 — 900 Total revenue $ 28,387 $ 3,006 $ 15,542 $ 46,935
Summary of Receivables and Contract Liabilities From Contracts with Customers	The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers. March 31, 2021 December 31, 2020 (In Thousands) Accounts receivable, gross $ 46,935 $ 45,792 Chargebacks and other deductions (17,264 ) (12,552 ) Provision for credit losses (9,482 ) (9,637 ) Accounts receivable, net $ 20,189 $ 23,603 Deferred revenue 1,289 1,147 Total contract liabilities $ 1,289 $ 1,147
Summary of Accounts Receivable and Contract Assets Balances by Reportable Segments	The following tables illustrate accounts receivable and contract asset balances by reportable segments. March 31, 2021 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 9,167 $ 3,589 $ 34,179 $ 46,935 Chargebacks and other deductions — — (17,264 ) (17,264 ) Provision for credit losses (8,919 ) (138 ) (425 ) (9,482 ) Accounts receivable, net 248 3,451 16,490 20,189 December 31, 2020 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 10,783 $ 4,074 $ 30,935 $ 45,792 Chargebacks and other deductions — (1 ) (12,551 ) (12,552 ) Provision for credit losses (8,919 ) (164 ) (554 ) (9,637 ) Accounts receivable, net $ 1,864 $ 3,909 $ 17,830 $ 23,603

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments Under Non-Cancelable Leases	Future minimum payments under the non-cancelable operating leases consists of the following as of March 31, 2021 (in thousands): Year ending December 31: Minimum payments 2021 (remaining nine months) $ 2,577 2022 2,918 2023 2,096 2024 2,002 2025 1,472 Thereafter 478 $ 11,543

Company and Nature of Business

Company and Nature of Business - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 738,694	$ 713,644
Cash and cash equivalents	47,980	69,587
Restricted cash	16,500
Short-term investments	$ 123,186	$ 138,636

Restricted Cash - Additional In

Restricted Cash - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Restricted Cash [Line Items]
Restricted cash	$ 16,500	$ 16,500
Senior Credit Agreement
Restricted Cash [Line Items]
Restricted cash	$ 16,500	$ 16,500
Period of interest on outstanding loans to be maintained in debt service reserve account	12 months

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 3,054	$ 6,498
Work in progress	1,728	776
Finished goods	21,542	21,572
Total inventories	$ 26,324	$ 28,846

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Identifiable Intangible Asset, Net (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Accumulated Amortization	$ 8,981,000	$ 8,260,000
Intangible asset, Effect of currency translation adjustment	(211,000)	(196,000)
Intangible assets Cost/Fair Value	18,463,000	18,478,000
Intangible assets, net	9,482,000	10,218,000
CDE In- Process Research and Development
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost/Fair Value	728,000	728,000
Indefinite-lived intangible asset, Net	728,000	728,000
Intangible assets Impairments	0
Licenses
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	12,641,000	12,641,000
Finite-lived intangible asset, Accumulated Amortization	5,745,000	5,157,000
Finite-lived intangible asset, Net	6,896,000	7,484,000
Polymed Customer List
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	1,593,000	1,593,000
Finite-lived intangible asset, Accumulated Amortization	1,482,000	1,418,000
Finite-lived intangible asset, Net	111,000	175,000
Polymed Technology
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	3,712,000	3,712,000
Finite-lived intangible asset, Accumulated Amortization	1,754,000	1,685,000
Finite-lived intangible asset, Net	$ 1,958,000	$ 2,027,000

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details)	3 Months Ended
	Mar. 31, 2021USD ($)Reporting_Unit	Mar. 31, 2020USD ($)
Finite Lived Intangible Assets [Line Items]
Weighted-average useful life of intangible assets	7 years 1 month 6 days
Amortization expense of intangible assets	$ 600,000	$ 500,000
Number of reporting units | Reporting_Unit	2
CDE In- Process Research and Development
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments	$ 0
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period	6 years
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period	12 years
Hanmi Pharmaceuticals Co. Ltd. | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 400,000
Acquired finite-lived intangible assets, amortization period	12 years 9 months
Gland Pharma Limited | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 4,400,000
Acquired finite-lived intangible assets, amortization period	5 years
MAIA Pharmaceuticals, Inc | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 4,000,000
Acquired finite-lived intangible assets, amortization period	7 years
Ingenus Pharmaceuticals, LLC | Licensing Agreements
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 3,000,000
Ingenus Pharmaceuticals, LLC | Licensing Agreements Amortized Over a Period of 5 years
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 2,000,000
Acquired finite-lived intangible assets, amortization period	5 years
Ingenus Pharmaceuticals, LLC | Licenses of Other Specialty Products
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 800,000
Ingenus Pharmaceuticals, LLC | Licensing Agreements Amortized Over a Period of 3 years
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 1,000,000
Acquired finite-lived intangible assets, amortization period	3 years

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets, Level 1 to Level 2 transfers	$ 0	$ 0
Fair value assets, Level 2 to Level 1 transfers	0	0
Fair value liabilities, Level 1 to Level 2 transfers	0	0
Fair value liabilities, Level 2 to Level 1 transfers	0	0
Fair value assets, transfers into Level 3	0	0
Fair value assets, transfers out of Level 3	0	0
Fair value liabilities, transfers into Level 3	0	0
Fair value liabilities, transfers out of Level 3	$ 0	$ 0
Pharma Essentia | OTC | Taiwan | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares owned by company	68,000	68,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Assets:
Total assets	$ 152,231	$ 188,181
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total assets	5,729	5,842
Significant Other Observable Inputs (Level 2)
Assets:
Total assets	146,502	182,339
Money Market Funds | Cash and Cash Equivalents
Assets:
Total assets	5,497	5,615
Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents
Assets:
Total assets	5,497	5,615
Short-term Investments - Certificates of Deposits | Short-term Investments
Assets:
Total assets	22,769	20,696
Short-term Investments - Certificates of Deposits | Cash and Cash Equivalents
Assets:
Total assets	1,000	4,070
Short-term Investments - Certificates of Deposits | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets	22,769	20,696
Short-term Investments - Certificates of Deposits | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Assets:
Total assets	1,000	4,070
Short-term Investments - Commercial Paper | Short-term Investments
Assets:
Total assets	85,185	102,715
Short-term Investments - Commercial Paper | Cash and Cash Equivalents
Assets:
Total assets	22,548	34,860
Short-term Investments - Commercial Paper | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets	85,185	102,715
Short-term Investments - Commercial Paper | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Assets:
Total assets	22,548	34,860
U.S. Government Bonds | Short-term Investments
Assets:
Total assets	15,000	14,998
U.S. Government Bonds | Cash and Cash Equivalents
Assets:
Total assets		5,000
U.S. Government Bonds | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets	15,000	14,998
U.S. Government Bonds | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Assets:
Total assets		5,000
Available-for-Sale Investment | Short-term Investments
Assets:
Total assets	232	227
Available-for-Sale Investment | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments
Assets:
Total assets	$ 232	$ 227

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Accrued wages and benefits	$ 7,798	$ 6,720
Accrued selling fees, rebates, and royalties	4,388	9,046
Accrued operating expenses	3,804	3,222
Accrued construction costs	3,421	4,104
Accrued inventory purchases	2,397	3,714
Accrued clinical expenses	2,073	2,949
Accrued tax withholdings	1,863	1,948
Accrued costs for product launch	1,415	1,474
Deferred revenue	1,289	1,147
Accrued R&D licensing fees	266	366
Accrued interest		3,583
Total accrued expenses	$ 28,714	$ 38,273

Accrued Expenses - Additional I

Accrued Expenses - Additional Information (Detail) - Dunkirk, NY - Manufacturing Facility $ in Millions	Mar. 31, 2021USD ($)
Accrued Liabilities [Line Items]
Accrued construction cost expected to be funded additional amount paid	$ 0.4
Prepaid Expenses and Other Current Assets
Accrued Liabilities [Line Items]
Accrued construction costs expected to be funded	$ 3.8

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax [Line Items]
Income tax expense (benefit)	$ 154,000	$ 2,881,000
Federal
Income Tax [Line Items]
Income tax expense (benefit)	0
Taiwan
Income Tax [Line Items]
Income tax expense (benefit)	$ 100,000

Debt and Lease Obligations - Su

Debt and Lease Obligations - Summary of Balances of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Current portion of mortgage	$ 729	$ 731
Current portion of bank loan	761	764
Current portion of senior secured loan	70	70
Current portion of finance lease obligations	410	445
Current portion of operating lease obligations	3,161	3,185
Long-term portion of finance lease obligations	474	537
Long-term portion of operating lease obligations	5,832	6,355
Total	158,229	158,127
Chongqing Maliu Credit Agreement
Debt Instrument [Line Items]
Chongqing Maliu credit agreement	7,614	7,641
Senior Secured Loan
Debt Instrument [Line Items]
Senior secured loan, net of debt discount and financing fees of $10,822 and $11,601 respectively	$ 139,178	$ 138,399

Debt and Lease Obligations - _2

Debt and Lease Obligations - Summary of Balances of Debt (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Senior Secured Loan
Debt Instrument [Line Items]
Debt discount and financing fees	$ 10,822	$ 11,601

Debt and Lease Obligations - Ad

Debt and Lease Obligations - Additional Information (Detail) ¥ in Millions	Jan. 05, 2021m²¥ / SquareMeter	Sep. 17, 2020	Aug. 04, 2020USD ($)	Jun. 19, 2020USD ($)Tranche	May 15, 2020USD ($)	Mar. 31, 2021USD ($)	Jun. 30, 2019CNY (¥)	Aug. 04, 2026USD ($)	Sep. 30, 2024USD ($)	Dec. 31, 2020USD ($)	May 15, 2020CNY (¥)
Debt Instrument [Line Items]
Mortgage payment extended date						Dec. 31, 2021
Chinese Subsidiaries | API Facility or Sintaho API Facility | Chongqing International Biological City Development & Investment Co., Ltd
Debt Instrument [Line Items]
Area of rent free lease | m²	34,517
Lease term	10 years
Renewal lease term	10 years
Payment of monthly rent per square meter | ¥ / SquareMeter	5
Chongqing Maliu Riverside Development and Investment Co., LTD ("CQ")
Debt Instrument [Line Items]
Line of credit facility percentage of periodic payment year one							20.00%
Line of credit facility percentage of periodic payment year two							30.00%
Line of credit frequency of payments						The Company is required to repay the principal amount with accrued interest within three years after the plant receives the cGMP certification, with 20% of the total loan with accrued interest is due within the first twelve months following receiving the certification, 30% of the total loan with accrued interest due within twenty-four months, and the remaining balance with accrued interest due within thirty-six months.
Line of credit due						$ 7,614,000				$ 7,641,000
China | Chongqing Maliu Riverside Development and Investment Co., LTD ("CQ")
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity							¥ 50			7,700,000
Long-term line of credit, interest rate							4.75%
Senior Credit Agreement
Debt Instrument [Line Items]
Number of tranches | Tranche				5
Debt maturity date						Jun. 19, 2026
Debt instrument, maximum borrowing capacity				$ 225,000,000
Interest rate terms						The loan bears interest at a fixed annual rate of 11.0%. The Company allocated the proceeds of the drawn tranches between liability and equity components and the fair value of such equity components, along with the direct costs related to the issuance of the debt were recorded as an offset to long-term debt on the consolidated balance sheets. The debt discount and financing fees are amortized on a straight-line basis, which approximates the effective interest method, over the remaining maturity of the Senior Credit Agreement. The effective interest rate of Tranches A, B and D, including the amortization of debt discount and financing fees amounts to 13.3% annually. The Company is required to make quarterly interest-only payments until June 19, 2022, after which the Company is required to make quarterly amortizing payments, with the remaining balance of the principal plus accrued and unpaid interest due at maturity.
Bearing interest at a fixed annual rate				11.00%
Frequency of payment						quarterly
Commitment fee percentage will be paid		0.60%
Exit fee liability						$ 3,000,000				$ 3,000,000
Minimum liquidity amount in cash or permitted cash equivalent investments amount				$ 20,000,000
Line of credit from first step up date until maturity				25,000,000
Line of credit facility second step up date outstanding amount				225,000,000
Line of credit from second step up date until maturity				$ 30,000,000
Minimum revenue percentage				50
Senior Credit Agreement | Minimum
Debt Instrument [Line Items]
Line of credit facility first step up date outstanding amount				$ 150,000,000
Senior Credit Agreement | Maximum
Debt Instrument [Line Items]
Covenant leverage ratio				4.50
Senior Credit Agreement | Tranche A,B and D
Debt Instrument [Line Items]
Debt instrument, amount drawn						150,000,000
Amortization of debt discount financing fees percentage				13.30%
Senior Credit Agreement | Tranche C 90 Days After Closing Date Through June 20, 2022
Debt Instrument [Line Items]
Available borrowing capacity upon satisfaction of regulatory and commercial milestones				$ 25,000,000
Senior Credit Agreement | Tranche E 90 Days After Closing Date Through June 19, 2023
Debt Instrument [Line Items]
Available borrowing capacity upon satisfaction of regulatory and commercial milestones				$ 50,000,000
Revenue Interest Financing Agreement | Sagard Healthcare Royalty Partners, LP
Debt Instrument [Line Items]
Licenses revenue			$ 50,000,000
Payment percentage of world-wide net sales			5.00%
Percentage of product payment			170.00%
Payments due to related parties			$ 85,000,000
Percentage of internal rate of return			6.00%
Revenue Interest Financing Agreement | Sagard Healthcare Royalty Partners, LP | Scenario Forecast
Debt Instrument [Line Items]
Payments due to related parties								$ 50,000,000	$ 20,000,000
Credit Agreement
Debt Instrument [Line Items]
Debt maturity date					May 14, 2021
Debt instrument, maximum borrowing capacity					$ 800,000
Bearing interest at a fixed annual rate					4.35%						4.35%
Debt instrument, amount drawn						$ 800,000
Credit Agreement | China
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity | ¥											¥ 5

Debt and Lease Obligations - _3

Debt and Lease Obligations - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Debt And Lease Obligations [Abstract]
Operating lease cost	$ 746	$ 755
Finance lease cost:
Amortization of assets	75	34
Interest on lease liabilities	24	6
Total net lease cost	$ 845	$ 795

Debt and Lease Obligations - Sc

Debt and Lease Obligations - Schedule of Supplemental Balance Sheet Information Related to Leases of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finance leases:
Property and equipment, at cost	$ 1,535	$ 1,535
Accumulated amortization, net	(422)	(347)
Property and equipment, net	1,113	$ 1,188
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]		Property and equipment, net
Current obligations of finance leases	410	$ 445
Long-term portion of finance leases	474	537
Total finance lease obligations	$ 884	$ 982
Weighted average remaining lease term (in years):
Operating leases	3 years 11 months 15 days	4 years 2 months 23 days
Finance leases	3 years 21 days	3 years 4 months 24 days
Weighted average discount rate:
Operating leases	12.80%	12.80%
Finance leases	10.80%	10.40%

Debt and Lease Obligations - _4

Debt and Lease Obligations - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash paid for amount included in the measurements of lease liabilities:
Operating cash flows from operating leases	$ (979)	$ (820)
Operating cash flows from finance leases	(24)	(6)
Financing cash flows from finance leases	$ (98)	(47)
ROU assets derecognized from modification of operating lease obligations		(468)
ROU assets recognized in exchange for operating lease obligations		$ 353

Debt and Lease Obligations - _5

Debt and Lease Obligations - Schedule of Future Minimum Payments and Maturities of Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Operating Leases
2021 (remaining nine months)	$ 2,577
2022	2,918
2023	2,096
2024	2,002
2025	1,472
Thereafter	478
Total lease payments	11,543
Less: Imputed interest	(2,550)
Total lease obligations	8,993
Less: Current obligations	(3,161)	$ (3,185)
Long-term lease obligations	5,832	6,355
Finance Leases
2021 (remaining nine months)	351
2022	275
2023	248
2024	157
Total lease payments	1,031
Less: Imputed interest	(147)
Total finance lease obligations	884	982
Less: Current obligations	(410)	(445)
Long-term portion of finance lease obligations	$ 474	$ 537

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	1 Months Ended		3 Months Ended			12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018Agreement	Mar. 31, 2021USD ($)Executiveshares	Dec. 31, 2020USD ($)shares	Mar. 31, 2020USD ($)	Dec. 31, 2020shares
Pharma Essentia
Related Party Transaction [Line Items]
Milestone fee earned			$ 500,000
Funds paid to related party			$ 0		$ 0
Nuwagen Limited
Related Party Transaction [Line Items]
Percentage of ownership interest of newly formed entity	10.00%
Avalon BioMedical
Related Party Transaction [Line Items]
Common stock shares held by related parties | shares			786,061	786,061		786,061
Percentage of common stock issued shares			1.00%			1.00%
Avalon BioMedical | Nuwagen Limited
Related Party Transaction [Line Items]
Percentage of ownership interest	90.00%
Avalon BioMedical | In-licensing Agreement
Related Party Transaction [Line Items]
Number of in-licensing agreements | Agreement		2
Milestone fee paid			$ 0		0
Axis Therapeutics Limited
Related Party Transaction [Line Items]
Licenses revenue				$ 1,000,000
License fee received withholding tax				$ 300,000
Executive Officer
Related Party Transaction [Line Items]
Number of executives | Executive			1
ZenRx
Related Party Transaction [Line Items]
Licenses revenue			$ 0		0
ZenRx | Clinical Development Services
Related Party Transaction [Line Items]
Payments to related party for services received			$ 300,000		$ 500,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 26, 2021	May 23, 2019	Mar. 31, 2021	Mar. 31, 2020	Jun. 14, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense			$ 2,280	$ 2,331
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense			2,205	1,864
Unrecognized compensation cost related to non-vested stock options expected to be recognized			$ 16,500
Unrecognized compensation expense related to non-vested stock options, weighted-average period of recognition			1 year 9 months 18 days
Total intrinsic value of stock options exercised			$ 200	800
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense			$ 29	$ 397
Unrecognized compensation expense related to non-vested stock options, weighted-average period of recognition			1 year 4 months 24 days
Shares granted to employees			0	0
Unrecognized cost related to non-vested restricted stock awards			$ 300
Maximum | Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense			$ 100
Maximum | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance					1,000,000
2017, 2013, 2007 and 2004 Plans | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock options authorized grant			16,000,000
2017 Omnibus Incentive Plan | Subsequent Event
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in stock available for issuance under plan	5,000,000
2017 Omnibus Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in stock available for issuance under plan		3,500,000
2017 Plans | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance			1,000,000
Stock-based compensation expense			$ 100	$ 100
Percentage of discount on purchase price of common stock			15.00%
Employee stock purchase plan, description			Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from December 1, 2020 to May 31, 2021. The Company expects to offer six-month offering periods after the current period.

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Stock Options
Stock Options, Outstanding Beginning Balance	12,496,888
Stock Options, Granted	20,000
Stock Options, Exercised	(119,425)
Stock Options, Forfeited and expired	(32,830)
Stock Options, Outstanding Ending Balance	12,364,633	12,496,888
Stock Options, Vested and exercisable	9,504,028
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 9.26
Weighted Average Exercise Price, Granted	11.90
Weighted Average Exercise Price, Exercised	7.10
Weighted Average Exercise Price, Forfeited and expired	12.92
Weighted Average Exercise Price, Outstanding Ending Balance	9.28	$ 9.26
Weighted Average Exercise Price, Vested and exercisable	$ 8.21
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term, Outstanding	5 years 2 months 12 days	5 years 5 months 1 day
Weighted Average Remaining Contractual Term, Vested and exercisable	4 years 3 months 10 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding		$ 22,463

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used as Inputs to Black-Scholes Option Pricing Model (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant date fair value	$ 7.40	$ 7.32
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	68.00%	67.00%
Risk-free interest rate	1.37%	0.75%
Expected life of options (in years)	6 years 3 months 18 days	5 years

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock-Based Compensation Cost (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 2,280	$ 2,331
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	2,205	1,864
Restricted Stock Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	29	397
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	46	70
Cost of Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	56	54
Research and Development Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	601	946
Selling, General, and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 1,623	$ 1,331

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders - Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	13,921,691	11,452,475
Stock Options and Other Common Stock Equivalents
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	13,899,191	11,347,475
Unvested Restricted Common Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	22,500	105,000

Business Segment, Geographic,_3

Business Segment, Geographic, and Concentration Risk Information - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)Segment	Mar. 31, 2020USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | Segment	3
Total revenue	$ 41,025	$ 46,935
Intersegment Eliminations
Segment Reporting Information [Line Items]
Total revenue	$ (1,106)	$ (708)
Segments Deriving Revenue
Segment Reporting Information [Line Items]
Number of reportable segments | Segment	2
Commercial Platform | Intersegment Eliminations
Segment Reporting Information [Line Items]
Total revenue	$ 600
Oncology Innovation Platform | Intersegment Eliminations
Segment Reporting Information [Line Items]
Total revenue	$ 500

Business Segment, Geographic,_4

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Segments (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total revenue:
Total consolidated revenue	$ 41,025	$ 46,935
Operating Segments
Total revenue:
Total consolidated revenue	42,131	47,643
Operating Segments | Oncology Innovation Platform
Total revenue:
Total consolidated revenue	20,665	28,387
Operating Segments | Global Supply Chain Platform
Total revenue:
Total consolidated revenue	8,207	3,714
Operating Segments | Commercial Platform
Total revenue:
Total consolidated revenue	13,259	15,542
Intersegment Eliminations
Total revenue:
Total consolidated revenue	(1,106)	$ (708)
Intersegment Eliminations | Oncology Innovation Platform
Total revenue:
Total consolidated revenue	500
Intersegment Eliminations | Commercial Platform
Total revenue:
Total consolidated revenue	$ 600

Business Segment, Geographic,_5

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Product Group (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total revenue by product group:
Total consolidated revenue	$ 41,025	$ 46,935
License Fees
Total revenue by product group:
Total consolidated revenue	20,500	28,381
Commercial Product Sales
Total revenue by product group:
Total consolidated revenue	18,061	17,502
API Sales
Total revenue by product group:
Total consolidated revenue	1,868	1,022
Contract Manufacturing Revenue
Total revenue by product group:
Total consolidated revenue	430	23
Other Revenue
Total revenue by product group:
Total consolidated revenue	$ 166	$ 7

Business Segment, Geographic,_6

Business Segment, Geographic, and Concentration Risk Information - Summary of Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (25,050)	$ (19,429)
Oncology Innovation Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(5,441)	(958)
Global Supply Chain Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(3,682)	(5,986)
Commercial Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (15,927)	$ (12,485)

Business Segment, Geographic,_7

Business Segment, Geographic, and Concentration Risk Information - Summary of Depreciation, Amortization and Assets by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Total depreciation and amortization:
Total consolidated depreciation and amortization	$ 1,274	$ 1,086
Total assets:
Total consolidated assets	349,656		$ 384,329
Oncology Innovation Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	207	175
Total assets:
Total consolidated assets	199,741		234,153
Global Supply Chain Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	523	496
Total assets:
Total consolidated assets	101,621		99,087
Commercial Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	544	$ 415
Total assets:
Total consolidated assets	$ 48,294		$ 51,089

Business Segment, Geographic,_8

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Geographical Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total revenue:
Total consolidated revenue	$ 41,025	$ 46,935
United States
Total revenue:
Total consolidated revenue	38,645	17,522
China
Total revenue:
Total consolidated revenue	205	28,513
Other Foreign Countries
Total revenue:
Total consolidated revenue	$ 2,175	$ 900

Business Segment, Geographic,_9

Business Segment, Geographic, and Concentration Risk Information - Summary of Property and Equipment by Geographical Segment (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Total property and equipment, net:
Total consolidated property and equipment, net	$ 41,778	$ 34,388
United States
Total property and equipment, net:
Total consolidated property and equipment, net	20,902	15,511
China
Total property and equipment, net:
Total consolidated property and equipment, net	$ 20,876	$ 18,877

Business Segment, Geographic_10

Business Segment, Geographic, and Concentration Risk Information - Summary of Customer Revenue and Accounts Receivable Concentration (Detail) - Commercial Platform and Global Supply Chain - Customer Concentration Risk	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Customer Revenue | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	49.00%	0.00%
Customer Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%	9.00%
Customer Revenue | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	9.00%	11.00%
Customer Revenue | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage	9.00%	7.00%
Customer Revenue | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%	60.00%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	36.00%		33.00%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	30.00%		24.00%
Accounts Receivable | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%		16.00%
Accounts Receivable | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%		6.00%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Revenue Recognition Milestone Method [Line Items]
Revenue recognition cash discount percentage	2.30%
Provision for chargebacks and other deductions included as reduction of accounts receivable total	$ 17,264,000	$ 12,552,000
Commercial Platform
Revenue Recognition Milestone Method [Line Items]
Provision for chargebacks and other deductions included as reduction of accounts receivable total	17,264,000	12,551,000
Chargebacks and other revenue deductions expense	25,600,000		$ 24,900,000
Axis Therapeutics Limited
Revenue Recognition Milestone Method [Line Items]
Licenses revenue		1,000,000
License fee received withholding tax		$ 300,000
Licensed IP
Revenue Recognition Milestone Method [Line Items]
Revenue recognized	0		$ 0
Transferred at a Point in Time | Licensed IP
Revenue Recognition Milestone Method [Line Items]
Revenue recognized	20,500,000
Revenue recognized for upfront fee upon transferring certain IP to customer	500,000
Transferred at a Point in Time | Licensed IP | 2017 Almirall Out-License Arrangement
Revenue Recognition Milestone Method [Line Items]
Revenue recognized upon achievement of first commercial milestone	$ 20,000,000

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Total revenue	$ 41,025	$ 46,935
Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	20,665	28,387
Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	7,101	3,006
Commercial Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	13,259	15,542
United States
Disaggregation Of Revenue [Line Items]
Total revenue	38,645	17,522
United States | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	20,157
United States | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	5,229	1,980
United States | Commercial Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	13,259	15,542
China
Disaggregation Of Revenue [Line Items]
Total revenue	205	28,513
China | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	8	28,308
China | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	197	205
Other Foreign Countries Including Austria
Disaggregation Of Revenue [Line Items]
Total revenue	2,175	900
Other Foreign Countries Including Austria | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	500	79
Other Foreign Countries Including Austria | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	$ 1,675	$ 821

Revenue Recognition - Summary o

Revenue Recognition - Summary of Receivables and Contract Liabilities From Contracts with Customers (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Change In Contract With Customer Liability [Abstract]
Accounts receivable, gross	$ 46,935	$ 45,792
Chargebacks and other deductions	(17,264)	(12,552)
Provision for credit losses	(9,482)	(9,637)
Accounts receivable, net	20,189	23,603
Deferred revenue	1,289	1,147
Total contract liabilities	$ 1,289	$ 1,147

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Accounts Receivable and Contract Assets Balances by Reportable Segments (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accounts Receivable By Reportable Segments [Line Items]
Accounts receivable, gross	$ 46,935	$ 45,792
Chargebacks and other deductions	(17,264)	(12,552)
Provision for credit losses	(9,482)	(9,637)
Accounts receivable, net	20,189	23,603
Oncology Innovation Platform
Accounts Receivable By Reportable Segments [Line Items]
Accounts receivable, gross	9,167	10,783
Provision for credit losses	(8,919)	(8,919)
Accounts receivable, net	248	1,864
Global Supply Chain Platform
Accounts Receivable By Reportable Segments [Line Items]
Accounts receivable, gross	3,589	4,074
Chargebacks and other deductions		(1)
Provision for credit losses	(138)	(164)
Accounts receivable, net	3,451	3,909
Commercial Platform
Accounts Receivable By Reportable Segments [Line Items]
Accounts receivable, gross	34,179	30,935
Chargebacks and other deductions	(17,264)	(12,551)
Provision for credit losses	(425)	(554)
Accounts receivable, net	$ 16,490	$ 17,830

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Payments Under Non-Cancelable Leases (Detail) $ in Thousands	Mar. 31, 2021USD ($)
Commitments And Contingencies Disclosure [Abstract]
2021 (remaining nine months)	$ 2,577
2022	2,918
2023	2,096
2024	2,002
2025	1,472
Thereafter	478
Total lease payments	$ 11,543

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021USD ($)Lawsuit
Commitments And Contingencies Disclosure [Abstract]
Number of purported securities class action lawsuits filed | Lawsuit	2
Liability related to class action lawsuit | $	$ 0

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Subsequent Event - Merger Agreement - Kuur Therapeutics, Inc.	May 04, 2021USD ($)
Subsequent Event [Line Items]
Upfront payment to stockholders in common stock	$ 70,000,000
Maximum
Subsequent Event [Line Items]
Milestone payments receivable	$ 115,000,000